This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Europäisches Patentamt European Patent Office

Office européen des brevets



(11) EP 0 704 530 A2

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication: 03.04.1996 Bulletin 1996/14

(21) Application number: 95112298.5

(22) Date of filing: 04.08.1995

(51) Int. Cl.⁶: **C12N 15/52**, C12N 15/65, C12N 1/21, C12N 15/74 // (C12N1/21, C12R1:01, 1:19)

(84) Designated Contracting States: CH DE FR GB LI

(30) Priority: 04.08.1994 JP 201582/94

(83) Declaration under Rule 28(4) EPC (expert solution)

(71) Applicant: NITTO CHEMICAL INDUSTRY CO., LTD. Tokyo (JP)

(72) Inventors:

Yu, Fuji
 Yokohama-shi, Kanagawa 227 (JP)

Kato, Mami
 Yokohama-shi, Kanagawa 235 (JP)

(74) Representative: VOSSIUS & PARTNER Siebertstrasse 4 D-81675 München (DE)

Remarks:

The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) A kanamycin resistance gene derived from microorganisms of the genus rhodococcus

(57) The present invention relates to a DNA derived from microorganisms of the genus <u>Rhodococcus</u> and conferring kanamycin resistance on hosts with a DNA sequence coding for the amino acid sequence of Sequence No. 1 or a polypeptide containing a partial sequence thereof. The kanamycin resistance gene of the present invention is useful to construct vectors for microorganisms of the genus <u>Rhodococcus</u>, particularly vectors for self-cloning of <u>Rhodococcus</u> rhodochrous.

Description

10

20

25

30

The present invention relates to a gene derived from microorganisms of the genus Rhodococcus and conferring kanamycin resistance on bacteria, as well as a plasmid vector containing the same.

Microorganisms belonging to the genus <u>Rhodococcus</u> are known as bacterial catalysts that hydrate or hydrolyze nitriles to the corresponding amides or acids (Japanese Patent Publication No. 4873/92 and Japanese Laid-Open Patent Publication Nos. 91189/87, 470/90 and 84198/90), and in particular, microorganisms belonging to the species <u>Rhodococcus rhodochrous</u> possess nitrile-hydrating activity of extremely high performance (Japanese Laid-Open Patent Publication No. 470/90).

Under such circumstances, one of the present inventors found cryptic plasmids in a certain strain of the species Rhodococcus rhodochrous and constructed hybrid plasmid vectors to develop a host-vector system of the genus Rhodococcus (Japanese Laid-Open Patent Publication Nos. 148685/92, 64589/93 and 68566/93).

For construction of a self-cloning system of higher safety, it is also necessary to develop marker genes derived from microorganisms of the genus <u>Rhodococcus</u>. However, only arsenious acid and cadmium resistance genes derived from microorganisms of the species <u>Rhodococcus</u> <u>rhodochrous</u> are known as such drug resistance genes (Plasmid <u>23</u>, 242-247 (1990)).

With the aim of establishing a self-cloning system of the genus Rhodococcus, the present inventors extensively studied drug resistance genes derived from microorganisms of the genus Rhodococcus, in particular the species Rhodococcus rhodochrous, so that they found the kanamycin resistance gene of the present invention.

That is, the present invention relates to a gene derived from microorganisms of the genus Rhodococcus and conferring kanamycin resistance on hosts, wherein said gene codes for the amino acid sequence of Sequence No. 1 or a polypeptide containing a partial sequence thereof.

The present invention furthermore relates to a gene conferring kanamycin resistance on a host comprising the DNA sequence of Sequence No. 2 or a DNA sequence which

(a) differs from said DNA sequence due to the degeneracy of the genetic code;

(b) hybridizes with said DNA sequence or the DNA sequence of (a); or

(c) represents a fragment, allelic or other variation of the above DNA sequence, whether said variation results in changes in the polypeptide sequence or not.

In this context, the term "hybridization" refers to conventional hybridization conditions, preferably to stringent hybridization conditions.

FIG. 1 shows a restriction enzyme map of plasmid pKM001.

FIG. 2 shows the construction of plasmid pKM002, pKM003 and pKM004.

FIG. 3 shows a restriction enzyme map of plasmid pKM011.

As the DNA donor in the present invention, mention may be made of kanamycin mutant KM-02 (deposited as FERM BP-5137 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology, Japan) which was obtained by spontaneous mutation of Rhodococcus rhodochrous ATCC 12674.

As the vectors used in cloning in the present invention, mention may be made of plasmid vectors including but not limited to <u>E</u>. <u>coli</u> vectors such as pTrc99A, pUC18, etc. and phage vectors such as λ gt11 etc. The host microorganisms include but are not limited to <u>E</u>. <u>coli</u> JM109, <u>E</u>. <u>coli</u> JM105, and <u>Rhodococcus rhodochrous</u> ATCC 12674.

Plasmids that provide plasmid vectors constructed of the kanamycin resistance gene of the invention with a region capable of replicating in microorganisms of the genus Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, but are not limited to, plasmids pRC001, pRC002, pRC003 and pRC004 are derived from Rhodococcus include, pRC004, pRC004,

The present kanamycin resistance gene derived from microorganisms of the genus <u>Rhodococcus</u> is useful to construct vectors for microorganisms of the genus <u>Rhodococcus</u>, particularly vectors for self-cloning of <u>Rhodococcus</u> rhodochrous.

The present invention is described in more detail with reference to the following examples, which however are not intended to limit the scope of the present invention.

Example 1

Cloning of Kanamycin Resistance Gene from Mutant KM-02 into E. coli JM109

5 (1) Preparation of genomic DNA from KM-02 and preparation of a DNA library

The KM-02 strain was cultured under shaking at 30 °C in 100 ml MY medium (0.5 % polypeptone, 0.3 % Bacto-yeast extract, 0.3 % Bacto-malt extract) and genomic DNA was prepared from the bacteria according to the method by Saito and Miura (Biochim. Biophys. Acta <u>72</u>, 619 (1963)). A part of the resulting DNA was partially digested with restriction enzyme <u>Sau</u>3AI and then inserted into a <u>Bam</u>HI site of <u>E. coli</u> vector pTrc99A to give a recombinant DNA library.

(2) Preparation of transformants and selection of recombinant DNA

The recombinant library prepared in step (1) was used to transform <u>E. coli</u> JM109 by the calcium chloride method, and transformants with resistance to kanamycin were selected in the following manner.

The transformants obtained above were plated onto LB agar medium (1 % Bacto-trypton, 0.5 % Bacto-yeast extract, 0.5 96 NaCl, 1.5 % agar) containing 40 μ g/ml kanamycin hydrochloride and 1 mM IPTG (isopropyl- β -thiogalactoside) and incubated overnight at 37 °C. The colonies occurring thereon were removed and applied onto the same agar medium, and their growth was confirmed.

A plasmid DNA was prepared from the thus obtained transformant according to the method by Birnboim and Doly (Nucleic Acid Res. 7, 1513-1523 (1979)) and designated pKM001. This plasmid was reintroduced into <u>E. coli</u>, and the resultant transformant with kanamycin resistance was designated JM109/pKM001 and deposited as FERM BP-5138 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology. IPTG was required for expression of Kanamycin resistance of <u>E. coli</u> JM109/pKM001.

(3) A restriction enzyme map of pKM001 and location of the kanamycin resistance gene

A restriction enzyme map of plasmid pKM001 obtained in step (2) was prepared (FIG. 1). Thereafter, this plasmid pKM001 was used for preparing plasmids of a smaller DNA fragment. The target gene-containing region was identified by the presence or absence of the kanamycin resistance of transformants prepared in the same manner as in step (2). During this process, plasmid pKM002 (FIG. 2) was constructed.

(4) Nucleotide sequencing

The nucleotide sequence of the kanamycin resistance gene in plasmid pKM002 was determined by Fluorescence Sequencer ALF II produced by Pharmacia (Sequence No. 3).

Example 2

20

25

Preparation of Hybrid (<u>E. Coli-Rhodococcus</u>) Plasmid Vector Carrying the Kanamycin Resistance Gene Derived from <u>Rhodococcus Rhodochrous</u>

A hybrid plasmid vector pK4, previously constructed by one of the present inventors by ligating <u>Rhodococcus</u>-derived plasmid pRC004 with <u>E. coli</u> vector pHSG299 and deposited as FERM BP-3731 with the National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology (Japanese Laid-Open Patent Publication Nos. 64589/93 and 68566/93), was used for preparing a 3.1 kb <u>Hind</u>III fragment containing the whole of pRC004 and a part of pHSG299, and the resulting fragment was ligated with the plasmid pKM002.

As a result, two plasmids carrying the insert in the opposite direction were obtained and designated pKM003 and pKM004, respectively (FIG. 2). These plasmids replicate in both the genus <u>Rhodococcus</u> and <u>E. coli</u>. <u>Rhodococcus</u> nhodochrous ATCC 12674 was transformed with these plasmids by electroporation, whereby a transformant capable of growing in MY medium containing 75 μ g/ml kanamycin was obtained. The plasmids obtained from the transformant were the same plasmids as those introduced. Where microorganisms of the genus <u>Rhodococcus</u> were used as the host, the presence of IPTG was not required for expression of kanamycin resistance.

Example 3

Construction of Vector for Microorganisms of the Genus Rhodococcus

The hybrid plasmid vector pKM004 was cleaved with restriction enzyme Kpnl to give a 4.3 kb Kpnl fragment which was then self-ligated and introduced into Rhodococcus rhodochrous ATCC 12674 by electroporation. The resulting transformant showed the same degree of kanamycin resistance as did the transformant of Example 2. From this trans-

formant, a plasmid was obtained and designated pKM011 (FIG. 3).

| | SEQUENCE TABLE | | | | | | | | | | | | | | | |
|----|----------------|------|------|------|------|------|-----|-----|------|------|------|-----|-----|-----|-----|-----|
| 5 | Seq | uenc | e No | o: 1 | _ | | | | | | | | | | | |
| | Len | gth: | 17 | 1 | | | | | | | | | | | | |
| | Seq | uenc | е Ту | pe: | ami | no a | cid | | | | | | | | | |
| 10 | Тор | olog | y: | line | ar | | | | | | | | | | | |
| | Nat | ure: | pr | otei | n | | | | | | | | | | | |
| 15 | Ori | gin | | | | | | • | | | | | | | | |
| | | | Mic | roor | gani | sm: | Rho | doc | occu | s rh | ođoc | hro | ıs | | | • |
| | | | Stra | in: | KM- | 02 | | | | | | | | | - | |
| 20 | Seq | uenc | e: | | | | | | | | | | | | | |
| | Met | Ser | Λsp | Λsn | Gly | Ser | Gly | Thr | Thr | Arg | Pro | Glu | Gly | Ala | Pro | Leu |
| | I | | | | 5 | | | | | 10 | | | | | 15 | |
| 25 | Pro | Arg | Arg | ۸la | ۸rg | Ser | Ser | ۸rg | Pro | Ser | Ala | Gly | Asn | Ser | Pro | Ala |
| | | | | 20 | | | | | 25 | | | | | 30 | | |
| 30 | Pro | Gly | ۸rg | Arg | Ala | Val | Val | ۸la | Lys | Ser | Arg | ۸rg | Arg | Leu | Ala | Ala |
| 30 | | | 35 | | | | | 40 | | | | | 45 | | | |
| | ۸la | Pro | Glu | Λla | Gly | Thr | Thr | His | Tyr | Ser | He | Phe | His | Gly | Asp | Gln |
| 35 | | 50 | | | | | 55 | | | | | 60 | | | | |
| | Leu | lle | Gly | Phe | He | Gin | Trp | Туг | Glu | Ala | Glu | Asp | Λsn | Pro | Asp | Phe |
| | 65 | | | | | 70 | | | | | 75 | | | | | 80 |
| 40 | Λrg | llis | ۸la | Gly | Leu | Asp | Leu | Phe | Leu | Λsp | Pro | Asp | Phe | His | Gly | Arg |
| | | | | | 85 | | | | | 90 | | | | | 95 | |
| | Gly | Phe | Gly | ۸rg | Glu | Ser | lle | Arg | Val | Leu | Cys | Ala | His | Leu | He | Asp |
| 45 | | | | 100 | | | | | 105 | | | | | 110 | | |
| | Asp | Leu | ۸la | Phe | llis | Arg | Leu | Val | He | Asp | Pro | Glu | Val | Asp | Asn | Ser |
| 50 | | | 115 | | | | | 120 | | | | | 125 | | | |
| | Val | Λla | lle | ۸la | Cys | Tyr | Arg | Ser | Val | Gly | Phe | Lys | Asp | Val | Gly | Val |
| | | 130 | | | | | 135 | | | | | 140 | | | | |

5

| | Sequence No: 2 | | | | | | | | | | | | | |
|----|---|-----|--|--|--|--|--|--|--|--|--|--|--|--|
| 5 | Length: 516 | | | | | | | | | | | | | |
| | Nature: nucleic acid | | | | | | | | | | | | | |
| | Strand Form: double-stranded | | | | | | | | | | | | | |
| 10 | Topology: linear | | | | | | | | | | | | | |
| | Origin | | | | | | | | | | | | | |
| 15 | Microorganism: Rhodococcus rhodochrous | | | | | | | | | | | | | |
| 15 | Strain: KM-02 | | | | | | | | | | | | | |
| | Sequence: | | | | | | | | | | | | | |
| 20 | ATG AGT GAC AAC GGC TCC GGA ACT ACG CGG CCC GAG GGT GCT CCT CTC | 48 | | | | | | | | | | | | |
| | CCC CGT CGC GCC CGA TCA TCA CGC CCG TCT GCG GGC AAT TCA CCT GCA | 96 | | | | | | | | | | | | |
| | CCC GGA CGT CGT GCA CTG GTG GCA AAA TCC CGA CGA CGA CTG GCT GCG | 144 | | | | | | | | | | | | |
| 25 | GCG CCA GAA GCC GGA ACC ACG CAC TAC AGC ATC TTC CAC GGC GAC CAA | 192 | | | | | | | | | | | | |
| | CTG ATC GGC TTC ATC CAG TGG TAC GAA GCG GAA GAC AAC CCC GAC TTC | 240 | | | | | | | | | | | | |
| 30 | CGC CAC GCC GGG CTC GAC TTG TTC CTC GAT CCC GAC TTC CAC GGC CGA | 288 | | | | | | | | | | | | |
| 30 | GGG TTC GGT CGC GAA TCG ATT CGC GTG CTG TGT GCC CAC CTG ATC GAC | 336 | | | | | | | | | | | | |
| | GAC CTC GCA TTC CAC CGT CTG GTC ATC GAC CCG GAG GTC GAC AAC TCC | 384 | | | | | | | | | | | | |
| 35 | GTC GCC ATC GCG TGC TAC CGA TCG GTG GGG TTC AAA GAC GTC GGG GTG | 432 | | | | | | | | | | | | |
| | ATG CGC GAG TAT TCG CGA GAT CGC CAT GGT GTG TGG AAG GAC GGA CTG | 480 | | | | | | | | | | | | |
| | CTG ATG GAT CTG CTC GCA CGG GAA TTC ATC CGC TGA | 516 | | | | | | | | | | | | |
| 40 | | | | | | | | | | | | | | |
| | Sequence No: 3 | | | | | | | | | | | | | |
| 45 | Length: 748 | | | | | | | | | | | | | |
| 45 | Sequence Type: nucleic Acid | | | | | | | | | | | | | |
| | Strand Form: double-stranded | | | | | | | | | | | | | |
| 50 | Topology: linear | | | | | | | | | | | | | |
| | Origin | | | | | | | | | | | | | |
| | Microorganism: Rhodococcus rhodochrous | | | | | | | | | | | | | |

Strain: KM-02

| 5 | Sequence: | | | | | | , |
|----|------------|------------|------------|------------|------------|------------|-----|
| | GGATCCGGGG | TCGTCGCCCA | CCAGGATGGT | ACCCAAGCCG | GGTGTGATGC | CCTCTGCCTT | 60 |
| 10 | CGAGCGCTCA | CCCGCACCTT | CAGGTCTTCG | AAGATTTCGT | CGCGGGTAGC | TTTGCCGTCG | 120 |
| | AGGATCGTTG | CAGTCACGGC | GACCATTGTT | CCAGGTTAGG | GTCGATGAGT | GACAACGGCT | 180 |
| | CCGGAACTAC | GCGGCCCGAG | CCTCCTC | TCCCCCGTCG | CGCCCGATCA | TCACGCCCGT | 240 |
| 15 | CTGCGGGCAA | TTCACCTGCA | CCCGGACGTC | GTGCAGTGGT | GGCAAAATCC | CGACGACGAC | 300 |
| | TGGCTGCGGC | GCCAGAAGCC | GGAACCACGC | ACTACAGCAT | CTTCCACGGC | GACCAACTGA | 360 |
| 20 | TCGGCTTCAT | CCAGTGGTAC | GAAGCGGAAG | ACAACCCCGA | CTTCCGCCAC | GCCGGGCTCG | 420 |
| | ACTTGTTCCT | CGATCCCGAC | TTCCACGGCC | GAGGGTTCGG | TCGCGAATCG | ATTCGCGTGC | 480 |
| | TGTGTGCCCA | CCTGATCGAC | GACCTCGCAT | TCCACCGTCT | GGTCATCGAC | CCGGAGGTCG | 540 |
| 25 | ACAACTCCGT | CGCCATCGCG | TGCTACCGAT | CGGTGGGGTT | CAAAGACGTC | GGGGTGATGC | 600 |
| | GCGAGTATTC | GCGAGATCGC | CATGGTGTGT | GGAAGGACGG | ACTGCTGATG | GATCTGCTCG | 660 |
| 30 | CACGGGAATT | CATCCGCTGA | TCGACTGGGA | CGAGTTCGAA | AGGACCGACA | TCATGTTGCT | 720 |
| | GGACAAGGAA | TTCACGGCCA | CCCTGCAG | | | | 748 |

SEQUENCE LISTING

| 5 | (1) GENERAL INFORMATION: |
|----|--|
| 10 | (i) APPLICANT: (A) NAME: Nitto Chemical Industry Co., Ltd. (B) STREET: 5-1, Marunouchi 1-chome, Chiyoda-ku (C) CITY: Tokyo (E) COUNTRY: Japan (F) POSTAL CODE (ZIP): 100 |
| 15 | (ii) TITLE OF INVENTION: A kanamycin resistance gene derived from microorganisms of the genus rhodococcus |
| | (iii) NUMBER OF SEQUENCES: 3 |
| 20 | (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO) |
| 25 | (v) CURRENT APPLICATION DATA: APPLICATION NUMBER: EP 95 11 2298.5 (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: JP 201582/1994 |
| | (B) FILING DATE: 04-AUG-1994 |
| 30 | (2) INFORMATION FOR SEQ ID NO: 1: |
| 35 | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 171 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear |
| | (ii) MOLECULE TYPE: protein |
| 40 | (vi) ORIGINAL SOURCE: (A) ORGANISM: Rhodococcus rhodochrous (B) STRAIN: KM-02 |
| 45 | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: |
| | Met Ser Asp Asn Gly Ser Gly Thr Thr Arg Pro Glu Gly Ala Pro Leu 1 5 10 15 |
| 50 | Pro Arg Arg Ala Arg Ser Ser Arg Pro Ser Ala Gly Asn Ser Pro Ala 20 25 30 |
| | Pro Gly Arg Arg Ala Val Ala Lys Ser Arg Arg Arg Leu Ala Ala |
| 55 | |

| | 35 | | | | | | 40 | | | | | 45 | | | | | | |
|----|---|------------|------------|------------|------------|---------------------|------------|------------|------------|------------|------------|------------|------------|------------|------------|-----------|------------|-----|
| 5 | | Ala | Pro 50 | Glu | Ala | Gly | Thr | Thr 55 | His | Tyr | Ser | Ile | Phe 60 | His | Gly | Asp | Gln | |
| | | Leu 65 | Ile | Gly | Phe | Ile | Gln 70 | Trp | Tyr | Glu | Ala | Glu 75 | Asp | Asn | Pro | Asp | Phe 80 | |
| 10 | | Arg | His | Ala | Gly | Leu 85 | Asp | Leu | Phe | Leu | Asp 90 | Pro | Asp | Phe | His | Gly 95 | Arg | |
| 15 | • | Gly | Phe | Gly | Arg 100 | Glu | Ser | Ile | Arg | Val 105 | Leu | Cys | Ala | His | Leu 110 | Ile | Asp | |
| | i | Asp | Leu | Ala 115 | Phe | His | Arg | Leu | Val 120 | Ile | Asp | Pro | Glu | Val 125 | Asp | Asn | Ser | |
| 20 | , | Val | Ala 130 | Ile | Ala | Суз | Tyr | Arg 135 | Ser | Val | Gly | Phe | Lys 140 | Asp | Val | Gly | Val | |
| | | Met 145 | Arg | Glu | Tyr | Ser | Arg 150 | Asp | Arg | His | Gly | Val 155 | Trp | Lys | Asp | Gly | Leu 160 | |
| 25 | 1 | Leu | Met | Asp | Leu | Leu 165 | Ala | Arg | Glu | Phe | Ile 170 | Arg | | | | | | |
| | (2) II | NFOR | MATI | ON F | OR S | EQ I | D NC |): 2: | | | | | | | | | | |
| 30 | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 516 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear | | | | | | | | | | | | | | | | | |
| 35 | | | | | | | | | | | | | | | | | | |
| | .(1 | /i) | (A) | ORG | ANIS | RCE: M: R KM- | hodo | cocc | us r | hodo | chro | us | | | | | | |
| 40 | | | | | | | | | | | | | • | | | | | |
| | (x) | ci) | SEQU | ENCE | DES | CRIP | TION | : SE | Q ID | NO: | 2: | | | | | | | |
| | ATGAGT | GAC. | A AC | GGCT | CCGG | AAC | TACG | CGG | CCCG | AGGG | TG C | TCCT | CTCC | c cc | GTCG | CGCC | ! | 60 |
| 45 | CGATCATCAC GCCCGTCTGC GGGCAATTCA CCTGCACCCG GACGTCGTGC AGTGGTGGCA 12 | | | | | | | | | | | | | 120 | | | | |
| | AAATCO | CGA | C GA | CGAC | TGGC | TGC | GGCG | CCA | GAAG | CCGG | AA C | CACG | CACT | A CA | GCAT | CTTC | , | 180 |
| 50 | CACGGC | GAC | C AA | CTGA | TCGG | CTT | CATC | CAG | TGGT | ACGA | AG C | GGAA | GACA | A CC | CCGA | CTTC | • | 240 |
| | CGCCAC | GCC | G GG | CTCG | ACTT | GTT | CCTC | GAT | CCCG | ACTT | CC A | CGGC | CGAG | g gt | TCGG | TCGC | | 300 |
| | GAATCG | ATT | C GC | GTGC | TGTG | TGC | CCAC | CTG | ATCG | ACGA | CC T | CGCA | TTCC | A CC | GTCT | GGTC | | 360 |
| 55 | | | | | | | | | | | | | | | | | | |

| 5 | ATCGACCCGG AGGTCGACAA CTCCGTCGCC ATCGCGTGCT ACCGATCGGT GGGGTTCAAA | 420 | | | | | | | | | | | |
|----|---|-----|--|--|--|--|--|--|--|--|--|--|--|
| | GACGTCGGGG TGATGCGCGA GTATTCGCGA GATCGCCATG GTGTGTGGAA GGACGGACTG | 480 | | | | | | | | | | | |
| | CTGATGGATC TGCTCGCACG GGAATTCATC CGCTGA | 516 | | | | | | | | | | | |
| 10 | (2) INFORMATION FOR SEQ ID NO: 3: | | | | | | | | | | | | |
| | (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 748 base pairs (B) TYPE: nucleic acid | | | | | | | | | | | | |
| 15 | (C) STRANDEDNESS: double (D) TOPOLOGY: linear | | | | | | | | | | | | |
| 20 | (vi) ORIGINAL SOURCE:(A) ORGANISM: Rhodococcus rhodochrous(B) STRAIN: KM-02 | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| 25 | (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: | | | | | | | | | | | | |
| | GGATCCGGGG TCGTCGCCCA CCAGGATGGT ACCCAAGCCG GGTGTGATGC CCTCTGCCTT | 60 | | | | | | | | | | | |
| | CGAGCGCTCA CCCGCACCTT CAGGTCTTCG AAGATTTCGT CGCGGGTAGC TTTGCCGTCG | 120 | | | | | | | | | | | |
| 30 | AGGATCGTTG CAGTCACGGC GACCATTGTT CCAGGTTAGG GTCGATGAGT GACAACGGCT | 180 | | | | | | | | | | | |
| | CCGGAACTAC GCGGCCCGAG GGTGCTCCTC TCCCCCGTCG CGCCCGATCA TCACGCCCGT | 240 | | | | | | | | | | | |
| | CTGCGGGCAA TTCACCTGCA CCCGGACGTC GTGCAGTGGT GGCAAAATCC CGACGACGAC | 300 | | | | | | | | | | | |
| 35 | TGGCTGCGGC GCCAGAAGCC GGAACCACGC ACTACAGCAT CTTCCACGGC GACCAACTGA | 360 | | | | | | | | | | | |
| | TCGGCTTCAT CCAGTGGTAC GAAGCGGAAG ACAACCCCGA CTTCCGCCAC GCCGGGCTCG | 420 | | | | | | | | | | | |
| 40 | ACTTGTTCCT CGATCCCGAC TTCCACGGCC GAGGGTTCGG TCGCGAATCG ATTCGCGTGC | 480 | | | | | | | | | | | |
| | TGTGTGCCCA CCTGATCGAC GACCTCGCAT TCCACCGTCT GGTCATCGAC CCGGAGGTCG | 540 | | | | | | | | | | | |
| | ACAACTCCGT CGCCATCGCG TGCTACCGAT CGGTGGGGTT CAAAGACGTC GGGGTGATGC | 600 | | | | | | | | | | | |
| 45 | GCGAGTATTC GCGAGATCGC CATGGTGTGT GGAAGGACGG ACTGCTGATG GATCTGCTCG | 660 | | | | | | | | | | | |
| | CACGGGAATT CATCCGCTGA TCGACTGGGA CGAGTTCGAA AGGACCGACA TCATGTTGCT | 720 | | | | | | | | | | | |
| 50 | GGACAAGGAA TTCACGGCCA CCCTGCAG | 748 | | | | | | | | | | | |

55 Claims

 A gene derived from a microorganism of the genus <u>Rhodococcus</u> and conferring kanamycin resistance on a host, said gene coding for the amino acid sequence of Sequence No. 1 or a polypeptide containing a partial sequence thereof.

EP 0 704 530 A2 2. The gene according to claim 1, comprising the DNA sequence of Sequence No. 2 or a partial sequence thereof. 3. A gene conferring kanamycin resistance on a host and comprising a DNA sequence which (a) differs from the DNA sequence of claim 2 in the codon sequence due to the degeneracy of the genetic code; (b) hybridizes with the DNA sequence of claim 2 or section (a), above; or (c) represents a fragment, allelic or other variation of the DNA sequence of claim 2, whether said variation results in changes in the polypeptide sequence or not. 4. The gene according to any one of claims 1 to 3, wherein the host microorganism is a microorganism of the genus Rhodococcus or Escherichia coli. 5. A plasmid vector comprising a gene according to any one of claims 1 to 4 and a DNA region capable of replicating in a microorganism of the genus Rhodococcus. 6. The plasmid vector according to claim 5, wherein the DNA region capable of replicating in a microorganism of the genus Rhodococcus is derived from a plasmid selected from pRC001, pRC002, pRC003 or pRC004. 7. A host cell transformed with the plasmid of claim 5 or 6. 8. The host cell of claim 7, which is a cell of a microorganism of the genus Rhodococcus or Escherichia coli. 9. Use of the gene of any one of claims 1 to 4 as a marker for the construction of a self-cloning system.

5

15

20

25

30


35


40

45

50

FIG.1








FIG.3

